Expanding Access to Low-Cost Generics Act of 2019

Bill: 116-s-3092
Sponsor: full_name: Sen. Smith, Tina [D-MN]
Introduced: 2019-12-18
Policy area: Health
Subjects: Civil actions and liability

Drug safety, medical device, and laboratory regulation

Intellectual property

Prescription drugs
Latest action: action_date: 2019-12-18
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summaries:
action_date: 2019-12-18
action_desc: Introduced in Senate
text: <p><b>Expanding Access to Low-Cost Generics Act of 2019</b> </p> <p>This bill modifies the 180-day exclusivity period for certain generic drug manufacturers.</p>

tv_txt: II 116th CONGRESS 1st Session S. 3092 IN THE SENATE OF THE UNITED STATES December 18, 2019 Ms. Smith (for herself and Mr. Braun ) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period, and for other purposes.

1. Short title This Act may be cited as the Expanding Access to Low-Cost Generics Act of 2019 . 2. 180-day exclusivity period (a) In general Section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j)(5)(B)(iv) ) is amended— (1) in subclause (I), by striking effective on the date that is 180 days after and all that follows through the period at the end and inserting the following: “effective— (aa) except as provided in item (bb), on the date that is 180 days after the date of the first commercial marketing of the drug (including the commercial marketing of the listed drug) by any first applicant; or (bb) if, in an infringement action brought in a district court solely against the applicant for the application described in this subclause (or any affiliate of the applicant), or an action in a district court for a declaratory judgment brought by that applicant, with respect to each patent to which a first applicant had submitted and lawfully maintained a certification under paragraph (2)(A)(vii)(IV), the district court decides that each patent is invalid or not infringed (including any substantive determination that there is no cause of action for patent infringement or invalidity), and the applicant for the application described in this subclause meets the requirements under subclause (III), immediately upon the district court entering such decision for such applicant. ; and (2) by adding at the end the following: (III) Applicant requirements The requirements under this subclause are that the applicant for the application described in subclause (I)— (aa) does not stay the action described in item (bb) of such subclause; (bb) does not agree to be bound by a judgment as to another applicant; and (cc) does not request joinder under section 42.122 of title 37, Code of Federal Regulations (or any corresponding similar regulation or ruling), for any petition that the applicant may have filed with respect to the application. . (b) Applicability The amendments made by subsection (a) shall apply only with respect to an application filed under section 505(j) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j) ) after the date of enactment of this Act that identifies a listed drug for which no certification under paragraph (2)(A)(vii)(IV) of such section was made before such date of enactment.